Rodriguez-Fontal Monica, Alfaro Virgil, Kerrison John B, Jablon Eric P
Charleston Neuroscience Institute, Retina Division, Charleston, SC 29414, USA.
Curr Diabetes Rev. 2009 Feb;5(1):47-51. doi: 10.2174/157339909787314239.
Ranibizumab (Lucentis) is a Fab-Antibody with high affinity for VEGF, and is being designed to bind to all VEGF isoforms. This quality makes it a powerful drug for VEGF inhibition. Diseases of retinal and choroidal blood vessels are the most prevalent causes of moderate and severe vision loss in developed countries. Vascular endothelial growth factor plays a critical role in the pathogenesis of many of these diseases. Results of the pilot studies showed that intraocular injections of ranibizumab (Lucentis) decrease the mean retinal thickness and improve the BCVA in all the subjects. Proliferative diabetic retinopathy, currently treated with destructive laser photocoagulation, represents another potential target for anti-VEGF therapy. The early experience in animal models with proliferative retinopathy and neovascular glaucoma shows that posterior and anterior neovascularizations are very sensitive to anti-VEGF therapy. The outcome of two phase III clinical trials will increase our knowledge of the role of Lucentis in the treatment of DME.
雷珠单抗（Lucentis）是一种对血管内皮生长因子（VEGF）具有高亲和力的Fab抗体，旨在与所有VEGF异构体结合。这一特性使其成为一种强大的VEGF抑制药物。视网膜和脉络膜血管疾病是发达国家中导致中度和重度视力丧失的最常见原因。血管内皮生长因子在许多此类疾病的发病机制中起着关键作用。初步研究结果表明，眼内注射雷珠单抗（Lucentis）可降低所有受试者的平均视网膜厚度并改善最佳矫正视力（BCVA）。目前采用破坏性激光光凝治疗的增殖性糖尿病视网膜病变是抗VEGF治疗的另一个潜在靶点。在增殖性视网膜病变和新生血管性青光眼动物模型中的早期经验表明，前后部新生血管对抗VEGF治疗非常敏感。两项III期临床试验的结果将增加我们对Lucentis在糖尿病性黄斑水肿（DME）治疗中作用的认识。
